PT2970964T - Composições de skipping de exões para o tratamento da distrofia muscular - Google Patents
Composições de skipping de exões para o tratamento da distrofia muscularInfo
- Publication number
- PT2970964T PT2970964T PT14723583T PT14723583T PT2970964T PT 2970964 T PT2970964 T PT 2970964T PT 14723583 T PT14723583 T PT 14723583T PT 14723583 T PT14723583 T PT 14723583T PT 2970964 T PT2970964 T PT 2970964T
- Authority
- PT
- Portugal
- Prior art keywords
- muscular dystrophy
- exon skipping
- treating muscular
- skipping compositions
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3535—Nitrogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361782706P | 2013-03-14 | 2013-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2970964T true PT2970964T (pt) | 2019-03-14 |
Family
ID=50694008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT14723583T PT2970964T (pt) | 2013-03-14 | 2014-03-14 | Composições de skipping de exões para o tratamento da distrofia muscular |
Country Status (26)
Country | Link |
---|---|
US (5) | US20140315977A1 (pt) |
EP (3) | EP3495485A3 (pt) |
JP (3) | JP2016521119A (pt) |
KR (4) | KR20210006516A (pt) |
CN (2) | CN105392884B (pt) |
AU (3) | AU2014236160A1 (pt) |
BR (1) | BR112015023038A2 (pt) |
CA (1) | CA2903872A1 (pt) |
CY (1) | CY1121876T1 (pt) |
DK (1) | DK2970964T3 (pt) |
EA (1) | EA201591694A1 (pt) |
ES (1) | ES2714290T3 (pt) |
HK (1) | HK1218138A1 (pt) |
HR (1) | HRP20190382T1 (pt) |
HU (1) | HUE042218T2 (pt) |
IL (2) | IL241047B (pt) |
LT (1) | LT2970964T (pt) |
MX (2) | MX366274B (pt) |
NZ (1) | NZ631132A (pt) |
PL (1) | PL2970964T3 (pt) |
PT (1) | PT2970964T (pt) |
RS (1) | RS58529B1 (pt) |
SA (1) | SA515361121B1 (pt) |
SI (1) | SI2970964T1 (pt) |
TR (1) | TR201903009T4 (pt) |
WO (1) | WO2014153240A2 (pt) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4272748A3 (en) | 2004-06-28 | 2024-03-27 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
EP2203173B1 (en) * | 2007-10-26 | 2015-12-23 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
JP5864257B2 (ja) | 2008-10-24 | 2016-02-17 | サレプタ セラピューティクス, インコーポレイテッド | Dmdのための複数のエキソンスキッピング組成物 |
CN105838714B (zh) | 2009-11-12 | 2020-07-17 | 西澳大利亚大学 | 反义分子和治疗疾病的方法 |
TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
EA035882B1 (ru) | 2013-03-14 | 2020-08-27 | Сарепта Терапьютикс, Инк. | Антисмысловые олигонуклеотиды, обеспечивающие пропуск экзонов, для лечения мышечной дистрофии |
BR112015022998A2 (pt) | 2013-03-15 | 2017-11-14 | Sarepta Therapeutics Inc | composições melhoradas para o tratamento de distrofia muscular |
FR3044926B1 (fr) | 2015-12-09 | 2020-01-31 | Genethon | Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine |
JOP20200228A1 (ar) | 2015-12-21 | 2017-06-16 | Novartis Ag | تركيبات وطرق لخفض تعبير البروتين tau |
WO2017205879A2 (en) | 2016-05-24 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
WO2017205880A1 (en) * | 2016-05-24 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
CN109311920B (zh) * | 2016-05-24 | 2021-11-09 | 萨勒普塔医疗公司 | 制备磷酸二酰胺吗啉代寡聚物的方法 |
MA45362A (fr) * | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | Procédés de préparation d'oligomères morpholino de phosphorodiamidate |
CN109563114B (zh) * | 2016-05-24 | 2022-08-12 | 萨勒普塔医疗公司 | 用于制备寡聚物的方法 |
KR102523527B1 (ko) * | 2016-06-30 | 2023-04-20 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 포스포로디아미데이트 모르폴리노 올리고머의 제조 방법 |
JP2019525742A (ja) * | 2016-06-30 | 2019-09-12 | サレプタ セラピューティクス, インコーポレイテッド | 筋ジストロフィーに対するエクソンスキッピングオリゴマー |
EP3485015A4 (en) * | 2016-07-15 | 2020-07-29 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS OF MODULATION OF DYSTROPHINE TRANSCRIPT |
CN116804031A (zh) * | 2016-09-20 | 2023-09-26 | 科罗拉多州立大学董事会法人团体 | 使用亚磷酰胺化学法合成主链修饰的吗啉代寡核苷酸和嵌合体 |
WO2018118627A1 (en) | 2016-12-19 | 2018-06-28 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
BR112019012647A2 (pt) | 2016-12-19 | 2019-11-19 | Sarepta Therapeutics Inc | conjugados de oligômero de salto de éxon para distrofia muscular |
AU2017382773A1 (en) * | 2016-12-19 | 2019-08-01 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
KR20200046069A (ko) * | 2017-08-31 | 2020-05-06 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근디스트로피를 치료하는 방법 |
EA201991450A1 (ru) * | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
EP3672601B1 (en) * | 2017-09-25 | 2023-09-13 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis |
EP3687519A1 (en) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
JP2021518361A (ja) * | 2018-03-16 | 2021-08-02 | サレプタ セラピューティクス, インコーポレイテッド | アンチセンス送達用キメラペプチド |
EP3784248A4 (en) * | 2018-04-26 | 2022-08-10 | Sarepta Therapeutics, Inc. | EXON-SKIPPING OLIGOMERS AND OLIGOMER CONJUGATE FOR MUSCLE DYSTROPHY |
US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
US20210220386A1 (en) * | 2018-06-14 | 2021-07-22 | Sarepta Therapeutics, Inc. | Exon skipping oligomers and oligomer conjugates for muscular dystrophy |
TW202035692A (zh) * | 2018-06-26 | 2020-10-01 | 日商日本新藥股份有限公司 | 含有反義寡核苷酸之組成物及其用於治療裘馨氏肌肉萎縮症之用途 |
CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
WO2020028864A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
WO2021025899A1 (en) | 2019-08-02 | 2021-02-11 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer pharmaceutical compositions |
EP4182315A1 (en) * | 2020-07-10 | 2023-05-24 | Changzhou Syntheall Pharmaceuticals Co., Ltd. | Processes for preparing oligonucleotides |
EP4314016A1 (en) | 2021-03-31 | 2024-02-07 | Entrada Therapeutics, Inc. | Cyclic cell penetrating peptides |
WO2022217366A1 (en) * | 2021-04-14 | 2022-10-20 | The Royal Institution For The Advancement Of Learning/Mcgill University | Modified oligonucleotides for the treatment of duchenne muscular dystrophy |
AU2022271873A1 (en) | 2021-05-10 | 2024-01-04 | Entrada Therapeutics, Inc. | Compositions and methods for intracellular therapeutics |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
WO2023178230A1 (en) * | 2022-03-17 | 2023-09-21 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH445129A (fr) | 1964-04-29 | 1967-10-15 | Nestle Sa | Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé |
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
US3453257A (en) | 1967-02-13 | 1969-07-01 | Corn Products Co | Cyclodextrin with cationic properties |
US3426011A (en) | 1967-02-13 | 1969-02-04 | Corn Products Co | Cyclodextrins with anionic properties |
US3453259A (en) | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
EP0215942B1 (en) | 1985-03-15 | 1995-07-12 | Antivirals Inc. | Polynucleotide assay reagent and method |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5149797A (en) | 1990-02-15 | 1992-09-22 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of rna and production of encoded polypeptides |
EP0786522A2 (en) | 1992-07-17 | 1997-07-30 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecules for treatment of stenotic conditions |
EP0698092B1 (en) | 1993-05-11 | 2007-07-25 | The University Of North Carolina At Chapel Hill | Antisense oligonucleotides which combat aberrant splicing and methods of using the same |
US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
WO1999042091A2 (en) | 1998-02-19 | 1999-08-26 | Massachusetts Institute Of Technology | Use of polycations as endosomolytic agents |
US6683173B2 (en) | 1998-04-03 | 2004-01-27 | Epoch Biosciences, Inc. | Tm leveling methods |
US6210892B1 (en) | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
WO2001047496A1 (en) | 1999-12-29 | 2001-07-05 | Mixson A James | Histidine copolymer and methods for using same |
US7070807B2 (en) | 1999-12-29 | 2006-07-04 | Mixson A James | Branched histidine copolymers and methods for using same |
EP1390490B1 (en) | 2001-05-24 | 2009-04-15 | Genzyme Corporation | Muscle-specific expression vectors |
CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
EP4272748A3 (en) | 2004-06-28 | 2024-03-27 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US8067571B2 (en) * | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
KR101789603B1 (ko) | 2005-11-10 | 2017-11-21 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | Tnf 수퍼패밀리 수용체에 대한 스플라이스 스위칭올리고머 및 염증성 질환 치료용 약제학적 조성물 |
JP2010505741A (ja) | 2006-05-10 | 2010-02-25 | エイブイアイ バイオファーマ, インコーポレイテッド | カチオン性のサブユニット間結合を有するオリゴヌクレオチドアナログ |
US20070265215A1 (en) * | 2006-05-11 | 2007-11-15 | Iversen Patrick L | Antisense restenosis composition and method |
US20100016215A1 (en) | 2007-06-29 | 2010-01-21 | Avi Biopharma, Inc. | Compound and method for treating myotonic dystrophy |
US8076476B2 (en) | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
US8299206B2 (en) | 2007-11-15 | 2012-10-30 | Avi Biopharma, Inc. | Method of synthesis of morpholino oligomers |
WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
US8084601B2 (en) * | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
JP5864257B2 (ja) * | 2008-10-24 | 2016-02-17 | サレプタ セラピューティクス, インコーポレイテッド | Dmdのための複数のエキソンスキッピング組成物 |
CN105838714B (zh) * | 2009-11-12 | 2020-07-17 | 西澳大利亚大学 | 反义分子和治疗疾病的方法 |
AU2011257980B2 (en) | 2010-05-28 | 2016-06-30 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
TWI541024B (zh) * | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
US9161948B2 (en) * | 2011-05-05 | 2015-10-20 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
KR102339196B1 (ko) | 2011-05-05 | 2021-12-15 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 펩타이드 올리고뉴클레오타이드 접합체 |
EP2750715B1 (en) * | 2011-08-30 | 2018-10-31 | The Regents of The University of California | Identification of small molecules that enhance therapeutic exon skipping |
CN104203289B (zh) * | 2012-01-27 | 2020-11-03 | 比奥马林技术公司 | 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
NZ700399A (en) * | 2012-03-20 | 2016-07-29 | Sarepta Therapeutics Inc | Boronic acid conjugates of oligonucleotide analogues |
KR20200143739A (ko) * | 2012-12-20 | 2020-12-24 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근위축증을 치료하기 위한 개선된 엑손 스키핑 조성물 |
-
2014
- 2014-03-14 DK DK14723583.2T patent/DK2970964T3/en active
- 2014-03-14 HU HUE14723583A patent/HUE042218T2/hu unknown
- 2014-03-14 US US14/213,641 patent/US20140315977A1/en not_active Abandoned
- 2014-03-14 TR TR2019/03009T patent/TR201903009T4/tr unknown
- 2014-03-14 LT LTEP14723583.2T patent/LT2970964T/lt unknown
- 2014-03-14 SI SI201431107T patent/SI2970964T1/sl unknown
- 2014-03-14 CN CN201480027371.7A patent/CN105392884B/zh active Active
- 2014-03-14 BR BR112015023038A patent/BR112015023038A2/pt not_active Application Discontinuation
- 2014-03-14 EP EP18215621.6A patent/EP3495485A3/en not_active Withdrawn
- 2014-03-14 NZ NZ631132A patent/NZ631132A/en unknown
- 2014-03-14 PL PL14723583T patent/PL2970964T3/pl unknown
- 2014-03-14 RS RS20190277A patent/RS58529B1/sr unknown
- 2014-03-14 PT PT14723583T patent/PT2970964T/pt unknown
- 2014-03-14 KR KR1020217000648A patent/KR20210006516A/ko not_active Application Discontinuation
- 2014-03-14 KR KR1020157028188A patent/KR20150133752A/ko not_active Application Discontinuation
- 2014-03-14 EP EP20182238.4A patent/EP3760720A1/en not_active Withdrawn
- 2014-03-14 WO PCT/US2014/029766 patent/WO2014153240A2/en active Application Filing
- 2014-03-14 EP EP14723583.2A patent/EP2970964B8/en active Active
- 2014-03-14 CN CN201811579820.5A patent/CN110066793A/zh active Pending
- 2014-03-14 KR KR1020227014526A patent/KR20220061280A/ko not_active Application Discontinuation
- 2014-03-14 CA CA2903872A patent/CA2903872A1/en active Pending
- 2014-03-14 MX MX2015012149A patent/MX366274B/es active IP Right Grant
- 2014-03-14 KR KR1020237016315A patent/KR20230074606A/ko not_active Application Discontinuation
- 2014-03-14 ES ES14723583T patent/ES2714290T3/es active Active
- 2014-03-14 EA EA201591694A patent/EA201591694A1/ru unknown
- 2014-03-14 US US14/776,533 patent/US20160040162A1/en not_active Abandoned
- 2014-03-14 JP JP2016503219A patent/JP2016521119A/ja not_active Withdrawn
- 2014-03-14 AU AU2014236160A patent/AU2014236160A1/en not_active Abandoned
-
2015
- 2015-09-02 IL IL241047A patent/IL241047B/en active IP Right Grant
- 2015-09-10 MX MX2019000224A patent/MX2019000224A/es unknown
- 2015-09-14 SA SA515361121A patent/SA515361121B1/ar unknown
-
2016
- 2016-05-26 HK HK16106036.5A patent/HK1218138A1/zh unknown
-
2017
- 2017-01-27 US US15/417,401 patent/US20180002689A1/en not_active Abandoned
-
2019
- 2019-02-27 HR HRP20190382TT patent/HRP20190382T1/hr unknown
- 2019-03-05 CY CY20191100267T patent/CY1121876T1/el unknown
- 2019-03-19 US US16/358,169 patent/US20200040336A1/en not_active Abandoned
- 2019-11-25 JP JP2019212294A patent/JP2020039362A/ja not_active Withdrawn
-
2020
- 2020-02-02 IL IL272415A patent/IL272415A/en unknown
- 2020-05-27 AU AU2020203473A patent/AU2020203473A1/en not_active Abandoned
-
2021
- 2021-12-17 JP JP2021204872A patent/JP2022031948A/ja active Pending
-
2022
- 2022-06-03 US US17/805,402 patent/US20220364093A1/en active Pending
- 2022-10-13 AU AU2022252769A patent/AU2022252769A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280443A (en) | Preparations that skip axon for the treatment of muscular dystrophy | |
IL272415A (en) | Preparations that skip axon for the treatment of muscular dystrophy | |
IL278912A (en) | Improved preparations for the treatment of muscular dystrophy | |
HK1216902A1 (zh) | 用作治療肌肉萎縮的改進外顯子跳躍組合物 | |
PL2984166T3 (pl) | Kompozycje do leczenia mpsi | |
SG11201602596UA (en) | Stabilized efinaconazole compositions | |
HK1209023A1 (en) | Procoagulant compounds | |
RS57977B1 (sr) | Tetrahidropirazolopirimidinska jedinjenja | |
AP2014007810A0 (en) | Imidazopyrrolidinone compounds | |
GB201304662D0 (en) | Compositions | |
EP2887803A4 (en) | PRO-NEUROGENIC COMPOUNDS | |
EP2828262A4 (en) | IMIDAZOTRIAZINONVERBINDUNGEN | |
PL2881439T3 (pl) | Kompozycje poliamidowe | |
GB201608461D0 (en) | Compositions | |
PL2878631T3 (pl) | Kompozycje poliamidowe | |
EP2897613A4 (en) | TREATMENT COMPOSITIONS | |
IL237483A0 (en) | Preparations for the treatment of psoriasis | |
EP2878302A4 (en) | COMPOSITION FOR PREVENTING OR TREATING OSTEOARTHRITIS | |
EP2973629A4 (en) | ELECTRODES FOR CONDENSERS BASED ON A MIXTURE OF CARBON COMPOSITIONS | |
GB201320962D0 (en) | Compositions | |
GB201320959D0 (en) | Compositions | |
GB201312224D0 (en) | Compositions | |
GB201218041D0 (en) | Methods compounds for preventing arthritis | |
GB201205504D0 (en) | Novel anti-proliferative compounds | |
GB201304927D0 (en) | Compositions |